Relationship between obesity, adipocytokines and inflammatory markers in type 2 diabetes: Relevance for cardiovascular risk prevention

International Journal of Environmental Research and Public Health

Volumn 11, Issue 4, 2014, Pages 4049-4065

  Rajkovic, Natasa ^a   Zamaklar, Miroslava ^a   Lalic, Katarina ^a   Jotic, Aleksandra ^a   Lukic, Ljiljana ^a   Milicic, Tanja ^a   Singh, Sandra ^a   Stosic, Ljubica ^a   Lalic, Nebojsa M ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Adipocytokines; Cardiovascular prevention; Diabetes; Inflammatory markers; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; INTERLEUKIN 6; LEPTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR SYSTEM; DIABETES; HEALTH RISK; OBESITY; RISK FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVENTION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

ADIPONECTIN; ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INTERLEUKIN-6; LEPTIN; MALE; MIDDLE AGED; OBESITY; RESISTIN; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898858718     PISSN: 16617827     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph110404049     Document Type: Article

References (65)

1. Eeg-Olofsson, K.; Cederholm, J.; Nilsson, P. M.; Zethelius, B.; Nunez, L.; Gudbjörnsdóttir, S.; Eliasson, B. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: An observational study in 13, 087 patients. Diabetologia 2009, 52, 65-73.
2. Kiadaliri, A.; Clarke, P. M.; Gerdtham, U. G.; Nilsson, P.; Eliasson, B.; Gudbjörnsdottir, S.; Steen, K. A. Predicting changes in cardiovascular risk factors in type 2 diabetes in the post-UKPDS era: Longitudinal analysis of the Swedish national diabetes register. Diabetes Res. 2013, 2013, doi: 10. 1155/2013/241347.
3. Gallagher, R.; Kirkness, A.; Zelestis, E.; Hollams, D.; Kneale, C.; Armari, E.; Bennett, T.; Daly, J.; Tofler, G. A randomised trial of a weight loss intervention for overweight and obese people diagnosed with coronary heart disease and/or type 2 diabetes. Ann. Behav. Med. 2012, 44, 119-128.
4. Espeland, M. A.; Rejeski, W. J.; West, D. S.; Action for Health in Diabetes Research Group. Intensive weight loss intervention in older individuals: Results from the action for health in diabetes type 2 diabetes mellitus trial. J. Amer. Geriat. Soc. 2013, 61, 912-922.
5. Hwang, C. L.; Wu, Y. T.; Chou, C. H. Effect of aerobic interval training on exercise capacity and metabolic risk factors in people with cardiometabolic disorders: A meta-analysis. J. Cardiopulm. Rehabil. Prev. 2011, 31, 378-385.
6. Gustafson, B. Adipose tissue, inflammation and atherosclerosis. J. Atheroscler. Thromb. 2010, 17, 332-341.
7. Calle, M. C.; Fernandez, M. L. Inflammation and type 2 diabetes. Diabetes Metab. 2012, 38, 183-191.
8. Bastard, J. P.; Maachi, M.; Lagathu, C.; Kim, M. J.; Caron, M.; Vidal, H.; Capeau, J.; Feve, B.; Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006, 17, 4-12.
9. Ouchi, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y.; Walsh, K. Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 2003, 14, 561-566.
10. Cnop, M.; Havel, P. J.; Utzschneider, K. M.; Carr, D. B.; Sinha, M. K.; Boyko, E. J.; Retzlaff, B. M.; Knopp, R. H.; Brunzell, J. D.; Kahn, S. E. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia 2003, 46, 459-469.
11. Weyer, C.; Funahashi, T.; Tanaka, S.; Hotta, K.; Matsuzawa, Y.; Pratley, R. E.; Tataranni, P. A. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 2001, 86, 1930-1935.
12. Hotta, K.; Funahashi, T.; Arita, Y.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.; Ouchi, N.; et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1595-1599.
13. Ouchi, N.; Kihara, S.; Arita, Y.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999, 100, 2473-2476.
14. Deng, G.; Long, Y.; Yu, Y. R.; Li, M. R. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int. J. Obesity 2010, 34, 165-171.
15. Brennan, A. M.; Li, T. Y.; Kelesidis, I.; Gavrila, A.; Hu, F. B.; Mantzoros, C. S. Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: A prospective cohort study. Diabetologia 2007, 50, 1178-1185.
16. Hajer, G. R.; van Haeften, T. W.; Visseren, F. L. J. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 2008, 29, 2959-2971.
17. Hartge, M. M.; Unger, T.; Kontscher, U. The endothelium and vascular inflammation in diabetes. Diab. Vasc. Res. 2007, 4, 84-88.
18. Qi, Q.; Wang, J.; Li, H.; Yu, Z.; Ye, X.; Hu, F. B.; Franco, O. H.; Pan, A.; Liu, Y.; Lin, X. Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur. J. Endocrinol. 2008, 159, 585-593.
19. Wallace, A. M.; McMahon, A. D.; Packard, C. J.; Kelly, A.; Shepherd, J.; Gaw, A.; Sattar, N.; The WOSCOPS Executive Committee. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001, 104, 3052-3056.
20. Wolk, R.; Berger, P.; Lennon, R. J.; Brilakis, E. S.; Johnson, B. D.; Somers, V. K. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J. Amer. Coll. Cardiol. 2004, 44, 1819-1824.
21. Vozarova de Courten, B.; Degawa-Yamauchi, M.; Considine, R. V.; Tataranni, P. A. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004, 53, 1279-1284.
22. Azuma, K.; Katsukawa, F.; Oguchi, S.; et al. Correlation between serum resistin level and adiposity in obese individuals. Obesity 2003, 11, 997-1001.
23. Youn, B. S.; YU, K. Y.; Park, H. J.; Roberts, C. K.; Manson, J. A. E.; Rifai, N.; Buring, J. E.; Gaziano, J. M.; Liu, S. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2004, 89, 150-156.
24. McTernan, P. G.; Fisher, F. M.; Valsamakis, G.; Chetty, R.; Harte, A.; MCternan, C. L.; Clark, P. M. S.; Smith, S. A.; Barnett, A. H.; Kumars, S. Resistin and type 2 diabetes: Regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J. Clin. Endocrinol. Metab. 2003, 88, 6098-6106.
25. Heilbronn, L. K.; Rood, J.; Janderova, L.; Albu, J. B.; Kelley, D. E.; Ravussin, E.; Smith, S. R. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J. Clin. Endocrinol. Metab. 2004, 89, 1844-1848.
26. Reilly, M. P.; Lehrke, M.; Wolfe, M. L.; Rohatgi, A.; Lazar, M. A.; Rader, D. J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111, 932-939.
27. Devaraj, S.; Singh, U.; Jialal, I. The evolving role of C-reactive protein in atherothrombosis. Clin. Chem. 2009, 55, 229-238.
28. Bastard, J. P.; Maachi, M.; van Nhieu, T. J.; Jardel, C.; Bruckert, E.; Grimaldi, A.; Robert, J. J.; Capeau, J.; Hainque, B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol Metab. 2002, 87, 2084-2089.
29. Pannacciulli, N.; Cantatore, F. P.; Minenna, A.; Bellacicco, M.; Giorgino, R.; de pergola, G. C-reactive protein is independetly associated with total body fat and insulin resistance in adult women. Int. J. Obesity 2001, 25, 1461-1420.
30. Fontana, L.; Eagon, J. C.; Trujillo, M. E.; Scherer, P. E.; Klein, S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56, 1010-1013.
31. Sola, E.; Jover, A.; López-Ruiz, A.; Jarabo, M.; Vayá, A.; Morillas, C.; Gómez-Balaguer, M.; Hernández-Mijares, A. Parameters of inflammation in morbid obesity: Lack of effect of moderate weight loss. Obes. Surg. 2009, 19, 571-576.
32. Bastard, J. P.; Jardel, C.; Bruckert, E.; Blondy, P.; Capeau, J.; Laville, M.; Vidal, H.; Hainque, B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol Metab. 2000, 85, 3338-3342.
33. Ziccardi, P.; Nappo, F.; Giugliano, G.; Esposito, K.; Marfella, R.; Cioffi, M.; D'Andrea, F.; Molinari, A. M.; Giugliano, D. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002, 105, 804-809.
34. Tilg, H.; Moschen, A. R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 2008, 14, 222-231.
35. Skalicky, J.; Muzakova, V.; Kandar, R.; Meloun, M.; Rousar, T.; Palicka, V. Evaluation of oxidative stress and inflammation in obese adults with metabolic syndrome. Clin. Chem. Lab. Med. 2008, 46, 499-505.
36. Olson, C. N.; Callas, W. P.; Hanley, A. J. G.; Festa, A.; Haffner, S. M.; Wagenknecht, L. E.; Tracy, R. P. Circulating levels od TNF are associated with impaired glucose tolerance, icreased insulin reistance, and ethinicity: The insulin resistance atherosclerosis study. J. Clin. Endocrinol. Metab. 2012, 97, 1032-1040.
37. Bahceci, M.; Gokalp, D.; Bahceci, S.; Tuzcu, A.; Atmaca, S.; Arikan, S. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high-sensitivity C-reactive protein levels. Is adipocyte size associated with the inflammation in adults? J. Endocrinol. Invest. 2007, 30, 210-214.
38. Skoog, T.; Dichtl, W.; Boquist, S.; Skoglund-Andersson, C.; Karpe, F.; Tang, R.; Bond, M. G.; de Faire, U.; Nilsson, J.; Eriksson, P.; Hamsten, A. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur. Heart J. 2002, 23, 376-383.
39. World Health Organization (WHO). Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation; WHO: Geneva, Switzerland, 2006.
40. National Committee for the Clinical Guidelines for Good Clinical Practice. Group for Diabetes. Nacionalni Vodič Dobre Kliničke Prakse Diabetes Mellitus; Agencija za Akreditaciju Zdravstvenih Ustanova Srbije: Beograd, Serbia, 2012.
41. Matthews, D. R.; Hosker, J. P.; Rudenski, A. S. Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 13, 412-419.
42. Goto, M.; Goto, A.; Morita, A; Deura, K.; Sasaki, S.; Aiba, N.; Shimbo, T.; Terauchi, Y.; Miyachi, M.; Noda, M.; Watanabe, S.; Saku Cohort Study Group. Low-molecular-weight adiponectin and high-molecular-weight adiponectinlevels in relation to diabetes. Obesity 2013, 1, doi: 10. 1002/oby. 20553.
43. Hasegawa, G.; Ohta, M.; Ichida, Y.; Obayashi, H.; Shigeta, M.; Yamasaki, M.; Fukui, M.; Yoshikawa, T.; Nakamura, N. Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity. Acta Diabetol. 2005, 42, 104-109.
44. Hansen, D.; Dendale, P.; Beelen, M.; Jonkers, R. A.; Mullens, A.; Corluy, L.; Meeusen, R.; van Loon, L. J. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur. J. Appl. Physiol. 2010, 109, 397-404.
45. Marita, A. R.; Sarkar, J. A.; Rane, S. Type 2 diabetes in non-obese Indian subjects is associated with reduced leptin levels: Study from Mumbai, western India. Mol. Cell. Biochem. 2005, 275, 143-151.
46. Yang, Y.; Lu, H. L.; Zhang, J.; Yu, H. Y.; Wang, H. W.; Zhang, M. X.; Cianflone, K. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs. obese type 2 diabetes. Int. J. Obesity 2006, 30, 439-446.
47. Gao, H.; Fall, T.; van Dam, R. M.; Flyvbjerg, A.; Zethelius, B.; Ingelsson, E.; Hägg, S. Evidence of a causal relationship between adiponectin levels and insulin sensitivity: A Mendelian randomization study. Diabetes 2013, 62, 1338-1344.
48. Abdelgadir, M.; Karlsson, A. F.; Berglund, L.; Berne, C. Low serum adiponectin concentrations are associated with insulin sensitivity independent of obesity in Sudanese subjects with type 2 diabetes mellitus. Diabetol. Metab. Synd. 2013, 5(1): 15. doi: 10. 1186/1758-5996-5-15.
49. Sayeed, M. A.; Khan, A. K. A.; Mahtab, H.; Ahsan, K. A.; Banu, A.; Khanam, P. A.; Ahrén, B. Leptin is reduced in lean subjects with type 2 diabetes in Bangladesh. Diabetes Care 2003, 26 doi: 10. 2337/diacare. 26. 2. 547.
50. Mohammadzadeh, G.; Zarghami, N. Serum leptin level is reduced in non-obese subjects with type 2 diabetes. Int. J. Endocrinol. Metab. 2013, 11, 3-10.
51. Mattu, H. S.; Randeva, H. S. Role of adipokines in cardiovascular disease. J. Endocrinol. 2013, 216, 17-36.
52. Morton, G. J.; Gelling, R. W.; Niswender, K. D.; Morrison, C. D.; Rhodes, C. J.; Schwartz, M. W. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell. Metab. 2005, 2, 411-420.
53. German, P. J.; Wisse, B. E.; Thaler, J. P.; Oh-I, S.; Sarruf, D. A.; Ogimoto, K.; Kaiyala, K. J.; Fischer, J. D.; Matsen, M. E.; Taborsky, G. J., Jr.; Schwartz, M. W.; Morton, G. J. Leptin deficiency causes insulin resistance induced by uncontrolled diabetes. Diabetes 2010, 59, 1626-1634.
54. Chanchay, S.; Tungtrongchitr, R.; Harnroongroj, T.; Phonrat, B.; Rungseesakorn, O.; Paksanont, S.; Pooudong, S.; Saowakontha, S.; Varongchayakul, C. Plasma resistin, insulin concentration in non-diabetic and diabetic, overweight/obese Thai. Int. J. Vitam. Nutr. Res. 2006, 76, 125-131.
55. Lee, J. H.; Chan, J. L.; Yiannakouris, N.; Kontogianni, M.; Estrada, E.; Seip, R.; Orlova, C.; Mantzoros, C. S. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J. Clin. Endocrinol. Metab. 2003, 88, 4848-4856.
56. Silha, J. V.; Krsek, M.; Skrha, J. V.; Sucharda, P.; Nyomba, B. L.; Murphy, L. J. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: Correlations with insulin resistance. Eur. J. Endocrinol. 2003, 149, 331-335.
57. Al Harithy, R. N.; Al Ghamdi, S. Serum resistin, adiposity and insulin resistance in Saudi women with type 2 diabetes mellitus. Ann. Saudi Med. 2005, 25, 283-287.
58. Nilsson, J.; Jovinge, S.; Niemann, A.; Reneland, R.; Lithell, H. Relationship between plasma tumor necrosis factor α and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 1199-1202.
59. Katsuki, A.; Sumida, Y.; Murashima, S.; Murata, K.; Takarada, Y.; Ito, K.; Fujii, M.; Tsuchihashi, K.; Goto, H.; Nakatani, K.; Yano, Y. Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1998, 83, 859-862.
60. Zinman, B.; Hanley, A. J. G.; Harris, S. B.; Kwan, J.; Fantus, I. G. Circulating tumor necrosis factor-α concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 1999, 84, 272-278.
61. Shamsuzzaman, A. S.; Winnicki, M.; Wolk, R.; Svatikova, A.; Phillips, B. G.; Davison, D. E.; Berger, P. B.; Somers, V. K. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004, 109, 2181-2185.
62. Van Dielen, F. M.; van't Veer, C.; Schols, A. M.; Soeters, P. B.; Buurman, W. A.; Greve, J. W. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int. J. Obes. Relat. Metab. Disord. 2001, 25, 1759-1766.
63. Gomez-Ambrosi, J.; Salvador, J.; Paramo, J. A.; Orbe, J.; de Irala, J.; Diez-Caballero, A.; Gil, M. J.; Cienfuegos, J. A.; Frühbeck, G. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin. Biochem. 2002, 35, 315-320.
64. Gomez-Ambrosi, J.; Salvador, J.; Silva, C.; Rotellar, F.; Gil, M. J.; Cienfuegos, J. A.; Frühbeck, G. Leptin therapy does not affect inflammatory markers. J. Clin. Endocrinol. Metab. 2005, 90, 3803.
65. Shetty, G. K.; Economides, P. A.; Horton, E. S.; Mantzoros, C. S.; Veves, A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004, 27, 2450-2457.